Physician profile
Eric Weldy
NPI 1154854990
$3,561.78
in general payments reported to CMS, 2019-2025
14 companies · $589 in 2025
The $589 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69.25 · 2021: $413 · 2022: $504 · 2023: $1,187 · 2024: $800 · 2025: $589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,536 · Education: $40.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,535.64 |
| Education | $40.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $567.01 | 2021-2025 | Vabysmo |
| Apellis Pharmaceuticals, INC. | $512.09 | 2023-2025 | Syfovre |
| Regeneron Healthcare Solutions, INC. | $494.88 | 2021-2025 | Eylea Hd |
| Astellas Pharma US INC | $344.13 | 2023-2025 | Izervay |
| Regeneron Pharmaceuticals, INC. | $335.93 | 2022-2023 | Eylea Hd |
| Alcon Vision LLC | $298.64 | 2019-2022 | |
| Alimera Sciences, INC. | $271.85 | 2022-2024 | Iluvien, Yutiq |
| Eyepoint US, INC. | $213.73 | 2021-2023 | |
| Notal Vision, INC. | $173.19 | 2024 | Foresee Home |
| Harrow Eye, LLC | $141.52 | 2024-2025 | Iheezo, Triesence |
| Genentech, INC. | $106.66 | 2022 | |
| Bausch & Lomb Americas INC. | $43.65 | 2023-2024 | Visudyne, Xipere |
| Mallinckrodt Hospital Products INC. | $29.38 | 2021 | |
| Coherus Oncology, INC. | $29.12 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Weldy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.